1.66 USD
▲+0.07+4.40%
盘后 1.63 -1.81%
2026-11-20
市值
$4.22M
市盈率
—
EPS
-1.43
股息率
—
52 周区间
0.72 – 4.50
成交量
77.45K
Beta
-1.03
目标价
—
52W 低 0.7252W 高 4.50
价格走势
公司简介
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.